These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30032935)

  • 21. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S; Lee YB; Choe SJ; Lee WS
    Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Finasteride adverse effects: An update].
    Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
    Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finasteride in benign prostatic hyperplasia.
    Wysowski DK; Farinas E
    N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15044649
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate, baldness drugs linked to sexual dysfunction.
    Kuehn BM
    JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk of Depression Associated With Finasteride Treatment.
    Pompili M; Magistri C; Maddalena S; Mellini C; Persechino S; Baldessarini RJ
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):304-309. PubMed ID: 33814544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
    Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
    World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.
    Da Silva MHA; Costa WS; B Sampaio FJ; De Souza DB
    Asian J Androl; 2018; 20(5):505-510. PubMed ID: 29893293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [How effective is finasteride?].
    Krome S
    Dtsch Med Wochenschr; 2011 Feb; 136(8):354. PubMed ID: 21348003
    [No Abstract]   [Full Text] [Related]  

  • 30. Post-finasteride syndrome: a surmountable challenge for clinicians.
    Traish AM
    Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
    Schmidt LJ; Tindall DJ
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
    Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
    J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormonal manipulation of benign prostatic hyperplasia.
    Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
    Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
    Pirozzi L; Sountoulides P; Castellan P; Presicce F; Lombardo R; Romero M; De Nunzio C; Tubaro A; Schips L; Cindolo L
    Curr Drug Targets; 2015; 16(11):1165-71. PubMed ID: 25981606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
    Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A
    Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):81-90. PubMed ID: 23173718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].
    Vinarov AZ; Spivak LG; Mironov AV
    Urologiia; 2017 Sep; (4):120-128. PubMed ID: 28952704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
    Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
    Kaplan SA
    J Urol; 2014 Mar; 191(3):752. PubMed ID: 24522062
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.